TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Survival B
Endpoint domain: Mortality/survival
Primary endpoint: Change of gastric emptying
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Venous lactate value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in BNA™ measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prothrombin Time (PT) Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Level of difficulty
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Routine test in the ward of total cholesterol, triglyceride, low-density lipoprotein and high-density lipoprotein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Violence Risk Screening
Endpoint domain: Adverse events/effects
Primary endpoint: Intra- and inter-operator reproducibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in cerebral vasodilatory reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cumulative incidence of IFD
Endpoint domain: Adverse events/effects
Primary endpoint: Median Progression-Free Survival Time
Endpoint domain: Mortality/survival
Primary endpoint: Percentage Change in HbA1c Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Skin colonisation in cfu/cm2 at the insertion site
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Colonisation of the CVC-tip, positivity by definition of number cfu/5cm > 15 (Maki-method)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of catheter-associated bloodstream infection
Endpoint domain: Adverse events/effects
Primary endpoint: Sellwood rating scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: SOFAS global functioning
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Titers for Serum H5N1 Haemagglutinin Inhibition (HI) Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seroconverted Subjects for H5N1 HI Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Morphotype/Phenotype expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTSD diagnosis and severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Integrated Muscle Protein Synthetic Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Erythema degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Occurrence of absent or weak signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in IntraMyoCellularLipid (IMCL) content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 24 hour sputum volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: cough severity (Leicester Cough Questionnaire)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Brachial endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Brachial artery stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Eye movement brain networks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Motor Seizure Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in acid-base balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LV pacing success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in Health Education Impact Questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Skeletal expansion at the level of the palatal median suture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of inclination of teeth and alveolar bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Perforation or Therapeutic Penetrating Keratoplasty
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Maximum Plasma Concentration of Sildenafil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration of Boceprevir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with abnormal gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Poststroke Depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MenC protection at 1-year post-MenACWY booster
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 6-hydroxymelatonin sulphate in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rescue analgesia time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in serum irisin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Untoward Event Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Endothelial function assessed by Flow Mediated Dilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: disease progression-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Urine concentration of fluconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Suppression of Peak LH Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Determination of DLT and MTD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of clinical efficacy according RECIST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of achieving spontaneous or artificial rupture of membranes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: System Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Psoriasis Area Severity Index (PASI) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annualized Rate of Confirmed Relapses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Daily Defined Doses of antihypertensive medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart rate variability pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: weight loss in kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continuation of breastfeeding
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Nasal hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects with closed ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) or Recommended Phase 2 Dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Task related Gamma band response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Cerebral Blood Volume (CBV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor Progression on Conventional MR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Patient-reported Outcome Measure of Symptoms and Their Impact in PAH
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Increase in reactivity of NST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from 0 to 24 hours at steady state (AUC0-24h,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Seroconverted Against 4 Strains of Influenza Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serological Profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants who experience a Dose-limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency and Severity of Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Position of the cochleostomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants With Clinically Significant Laboratory Abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Asynchrony Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of dose limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Perceived Risk
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Worry about Harms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Intention to Try or Quit
Endpoint domain: Life impact
Endpoint subdomain: Behavioral intention
Primary endpoint: Change From Baseline Trough in 24-hour Weighted-mean FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Abiraterone AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in flow velocities at the CVJ and aqueduct of Sylvius
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Progression Free Survival Probability
Endpoint domain: Mortality/survival
Primary endpoint: total and replication-competent reservoir (RCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pupil Diameter (Change From Max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of participants with lymphoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline in Daily Average Bladder Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Severe Acute Graft Versus Host Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Heavy Drinking Days Per Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COVID vaccination rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in physical activity measures
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: % of patients with Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: time to lung transplantation or death due to IPF
Endpoint domain: Mortality/survival
Primary endpoint: Post-operative Nausea or Vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Acceptability of the decision support tool
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in patient's knowledge of contralateral prophylactic mastectomy (CPM)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reductions in decisional conflict about CPM
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ACL Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 28-day Seizure Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of American Orthopedic Foot and Ankle (AOFAS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Ankle volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Volume of Mucin Per Surface Area of Basal Lamina
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performance characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scar severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Post-prandial blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Central Sensitisation Inventory score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ETS exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incretin hormone response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes From Baseline in Markers of Oxidative Stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of HIV-1 Infections of Tenofovir 1% Gel and Vaginal Placebo Gel Arms
Endpoint domain: Mortality/survival
Primary endpoint: Number of HIV-1 Infections of Oral TDF and Oral Placebo Arms
Endpoint domain: Mortality/survival
Primary endpoint: Number of HIV-1 Infections of Oral TDF-FTC and Oral Placebo Arms
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of patients achieving HbA1c below 7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to first spontaneous void
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Comparison of RPVi to SVV and/or PPV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of CAS and AAA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mental health state (anxiety)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mental health state (Depression)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Muscle cross-sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Quality of life score measured by EQ-5D-5L
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Safety - incidence of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: self-reported moderate/vigorous physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean STAI-1 score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in International index of erectile function score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: TB relapse and reinfection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of participants with five percent or greater weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Screening rate for hepatitis B
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean of the 24-hour Standard Deviation Score (SDS) Profile for 17-OHP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to identification of first lymph node
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Total Symptom Score (TSS) Reduction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 24-hour Activity Level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Diagnostic accuracy of MR-FFR measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Main cardiac events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prenatal attachment inventory (PAI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Acceptability of REBOOT
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Presence or absence of AVM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Plasma levels of eltrombopag
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protein binding of eltrombopag
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Endometrial Hyperplasia or Worse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: improvement of HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Level of Interleukin 8 in pulpal blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Fatigue scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Changes in Daily Functioning - Pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Effectiveness of Lactobacillus acidophilus supplements in treating oral candidiasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in work ability
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Percentage of CD49d expressing neutrophils in nasal lavage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 30-day smoking abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported quit attempts
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Use of evidence-based smoking cessation resources
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adjusted Mean Change From Baseline in A1C Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Measurement of subsets of WBC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in BOLD response after CGRP infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in BOLD response after injection of sumatriptan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Characteristic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24h proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Acceptability of the Intervention and participants' experiences
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Compliance with intervention protocol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of IGg seropositive health care workers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Metaprolol concentration in blood serum (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of grade 3/4 immune-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Response rate according to RECIST 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RFS at 24 months in patients achieving pCR or pnCR
Endpoint domain: Mortality/survival
Primary endpoint: Change in substance dependence severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in baseline osteoarticular pain at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in baseline functional limitation at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pharmacokinetic equivalence to Remicade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of congenital HCMV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Clinical outcome of congenital HCMV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in SAE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in the number of endothelial progenitor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapy adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of cesarean section for intrapartum fetal distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change in PROMIS Pain Interference questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Hippocampal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Hippocampus glial activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change PAG opioid binding potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Asthma Exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes